| __timestamp | Blueprint Medicines Corporation | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 17763000 |
| Thursday, January 1, 2015 | 14456000 | 22180000 |
| Friday, January 1, 2016 | 19218000 | 37257000 |
| Sunday, January 1, 2017 | 27986000 | 27367000 |
| Monday, January 1, 2018 | 47928000 | 64770000 |
| Tuesday, January 1, 2019 | 96388000 | 74986000 |
| Wednesday, January 1, 2020 | 157743000 | 79256000 |
| Friday, January 1, 2021 | 195293000 | 100156000 |
| Saturday, January 1, 2022 | 237374000 | 131408000 |
| Sunday, January 1, 2023 | 295141000 | 152946000 |
| Monday, January 1, 2024 | 359272000 |
Unlocking the unknown
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. Blueprint Medicines Corporation and Dynavax Technologies Corporation, two prominent players in the industry, have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Blueprint Medicines saw a staggering increase in SG&A expenses, growing nearly 3,700% from approximately $7.9 million to $295 million. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Dynavax Technologies experienced a more moderate rise of about 760%, from $17.8 million to $153 million, indicating a more conservative approach to scaling operations.
These trends highlight the diverse strategies employed by biotech firms in managing costs while pursuing growth, offering valuable insights for investors and industry stakeholders.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Summit Therapeutics Inc. vs Blueprint Medicines Corporation: SG&A Expense Trends
Blueprint Medicines Corporation or Veracyte, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Mesoblast Limited
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.